Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Mannequinon Feb 27, 2024 9:41am
50 Views
Post# 35901113

RE:Both F8 and Trogarzo IM

RE:Both F8 and Trogarzo IMSo does this event now help us cut back on more expenses now?  
scarlet1967 wrote: After Trogarzo IM study the company said they will be getting expert advice before submitting the application, during the earning call Paul also said they are working with experts.. yet ... the first offering when "share price was ridiculous" , their NASH asset went from Hero  to Zero, cure to cancer and then the abrupt stop ,  bunch of new hiring followed recently by two rounds of lay offs of their R&D to cut costs, the Marathon disaster and lastly the latest offering yet two million dollars salary for the CEO who has been overseeing both commercial and R&D operations. As for commercial sales have been up and down and overall not as promising as what one would expect from the marketing genius (CEO) as per R&D...,
It might not make a hug difference whether IM is approved or not but the loss of credibility due to these missteps in marketing, executions , and bunch of financial missteps will make a difference to how investors grade the management team and its leader the CEO. Point is every and each decision made has to be approved by Paul and ultimately he is responsible for the consequences and yes I don't think he has been able to make any meaningful difference since his arrival on the contrary ... 
Speachless 


<< Previous
Bullboard Posts
Next >>